Literature DB >> 29768941

Bilirubin and oxidative stress in term and preterm infants.

Carlo Dani1,2, Chiara Poggi1, Simone Pratesi1.   

Abstract

Hyperbilirubinemia is the most frequent clinical problem neonatologists must deal with during the newborn period. It has been suggested that bilirubin is involved in the balance between antioxidant and pro-oxidant agents due to its antioxidant properties. However, the relevance of these effects in vivo in term and preterm infants is still debated. We performed a literature review of studies that investigated the association between total serum bilirubin (TSB) and oxidative stress in newborn infants. We found that studies in term infants give contradictory results, while studies in preterm infants suggest that the TSB increase is associated with an oxidative stress increase due to concurrent factors other than bilirubin level, such as heme oxygenase (HO) activity. Moreover, it could be speculated that low physiologic TSB values are associated with antioxidant effects, while high pathologic TSB values are associated with pro-oxidant effects. Literature data do not allow the establishment of whether if the antioxidant properties of bilirubin are important from a clinical point of view and can affect the outcome in ill infants.

Entities:  

Keywords:  Bilirubin; oxidative stress; preterm infant; term infant

Mesh:

Substances:

Year:  2018        PMID: 29768941     DOI: 10.1080/10715762.2018.1478089

Source DB:  PubMed          Journal:  Free Radic Res        ISSN: 1029-2470


  9 in total

1.  Bile acids profile and redox status in healthy infants.

Authors:  Alice Santos-Silva; Dora Brites; Ermelinda Santos Silva; Susana Rocha; Rita Candeias Ramos; Helena Coutinho; Cristina Catarino; Fernanda Teixeira; Graça Henriques; Ana Isabel Lopes
Journal:  Pediatr Res       Date:  2022-10-22       Impact factor: 3.953

Review 2.  Pharmaceutical strategies for preventing toxicity and promoting antioxidant and anti-inflammatory actions of bilirubin.

Authors:  Alessio Nocentini; Alessandro Bonardi; Simone Pratesi; Paola Gratteri; Carlo Dani; Claudiu T Supuran
Journal:  J Enzyme Inhib Med Chem       Date:  2022-12       Impact factor: 5.051

3.  Clinical Assessment of Neuroinflammatory Markers and Antioxidants in Neonates with Hyperbilirubinemia and Their Association with Acute Bilirubin Encephalopathy.

Authors:  Dina Abdel Razek Midan; Wael A Bahbah; Noha Rabie Bayomy; Noha M Ashour
Journal:  Children (Basel)       Date:  2022-04-14

4.  Plant-derived oleanolic acid ameliorates markers associated with non-alcoholic fatty liver disease in a diet-induced pre-diabetes rat model.

Authors:  Mlindeli Gamede; Lindokuhle Mabuza; Phikelelani Ngubane; Andile Khathi
Journal:  Diabetes Metab Syndr Obes       Date:  2019-10-01       Impact factor: 3.168

5.  Deceased serum bilirubin and albumin levels in the assessment of severity and mortality in patients with acute pancreatitis.

Authors:  Xiao Xu; Fen Ai; Min Huang
Journal:  Int J Med Sci       Date:  2020-09-23       Impact factor: 3.738

Review 6.  Two Faces of Heme Catabolic Pathway in Newborns: A Potential Role of Bilirubin and Carbon Monoxide in Neonatal Inflammatory Diseases.

Authors:  Wiktoria Osiak; Sławomir Wątroba; Lucyna Kapka-Skrzypczak; Jacek Kurzepa
Journal:  Oxid Med Cell Longev       Date:  2020-08-18       Impact factor: 6.543

Review 7.  Bilirubin-Induced Neurological Damage: Current and Emerging iPSC-Derived Brain Organoid Models.

Authors:  Abida Islam Pranty; Sara Shumka; James Adjaye
Journal:  Cells       Date:  2022-08-25       Impact factor: 7.666

8.  Maternal disease factors associated with neonatal jaundice: a case-control study.

Authors:  Youngjae Yu; Jinwha Choi; Myeong Hoon Lee; KangHyun Kim; Hyun Mee Ryu; Hyun Wook Han
Journal:  BMC Pregnancy Childbirth       Date:  2022-03-24       Impact factor: 3.007

9.  A nomogram to predict in-hospital mortality of neonates admitted to the intensive care unit.

Authors:  Xihua Huang; Zhenyu Liang; Tang Li; Yu Lingna; Wei Zhu; Huiyi Li
Journal:  Int Health       Date:  2021-12-01       Impact factor: 2.473

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.